MARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation

ABSTRACT Membrane-associated RING-CH-type 8 (MARCH8) strongly blocks human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) incorporation into virions by downregulating its cell surface expression, but the mechanism is still unclear. We now report that MARCH8 also blocks the Ebola v...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Changqing Yu, Sunan Li, Xianfeng Zhang, Ilyas Khan, Iqbal Ahmad, Yulong Zhou, Shuo Li, Jing Shi, Yu Wang, Yong-Hui Zheng
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2020
Materias:	Ebola HIV MARCH8 class I fusion protein furin glycosylation Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/2072e260d8684d80bb2cee0ec0199e67
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2072e260d8684d80bb2cee0ec0199e67
record_format	dspace
spelling	oai:doaj.org-article:2072e260d8684d80bb2cee0ec0199e672021-11-15T16:19:09ZMARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation10.1128/mBio.01882-202150-7511https://doaj.org/article/2072e260d8684d80bb2cee0ec0199e672020-10-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.01882-20https://doaj.org/toc/2150-7511ABSTRACT Membrane-associated RING-CH-type 8 (MARCH8) strongly blocks human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) incorporation into virions by downregulating its cell surface expression, but the mechanism is still unclear. We now report that MARCH8 also blocks the Ebola virus (EBOV) glycoprotein (GP) incorporation via surface downregulation. To understand how these viral fusion proteins are downregulated, we investigated the effects of MARCH8 on EBOV GP maturation and externalization via the conventional secretion pathway. MARCH8 interacted with EBOV GP and furin when detected by immunoprecipitation and retained the GP/furin complex in the Golgi when their location was tracked by a bimolecular fluorescence complementation (BiFC) assay. MARCH8 did not reduce the GP expression or affect the GP modification by high-mannose N-glycans in the endoplasmic reticulum (ER), but it inhibited the formation of complex N-glycans on the GP in the Golgi. Additionally, the GP O-glycosylation and furin-mediated proteolytic cleavage were also inhibited. Moreover, we identified a novel furin cleavage site on EBOV GP and found that only those fully glycosylated GPs were processed by furin and incorporated into virions. Furthermore, the GP shedding and secretion were all blocked by MARCH8. MARCH8 also blocked the furin-mediated cleavage of HIV-1 Env (gp160) and the highly pathogenic avian influenza virus H5N1 hemagglutinin (HA). We conclude that MARCH8 has a very broad antiviral activity by prohibiting different viral fusion proteins from glycosylation and proteolytic cleavage in the Golgi, which inhibits their transport from the Golgi to the plasma membrane and incorporation into virions. IMPORTANCE Enveloped viruses express three classes of fusion proteins that are required for their entry into host cells via mediating virus and cell membrane fusion. Class I fusion proteins are produced from influenza viruses, retroviruses, Ebola viruses, and coronaviruses. They are first synthesized as a type I transmembrane polypeptide precursor that is subsequently glycosylated and oligomerized. Most of these precursors are cleaved en route to the plasma membrane by a cellular protease furin in the late secretory pathway, generating the trimeric N-terminal receptor-binding and C-terminal fusion subunits. Here, we show that a cellular protein, MARCH8, specifically inhibits the furin-mediated cleavage of EBOV GP, HIV-1 Env, and H5N1 HA. Further analyses uncovered that MARCH8 blocked the EBOV GP glycosylation in the Golgi and inhibited its transport from the Golgi to the plasma membrane. Thus, MARCH8 has a very broad antiviral activity by specifically inactivating different viral fusion proteins.Changqing YuSunan LiXianfeng ZhangIlyas KhanIqbal AhmadYulong ZhouShuo LiJing ShiYu WangYong-Hui ZhengAmerican Society for MicrobiologyarticleEbolaHIVMARCH8class I fusion proteinfuringlycosylationMicrobiologyQR1-502ENmBio, Vol 11, Iss 5 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ebola HIV MARCH8 class I fusion protein furin glycosylation Microbiology QR1-502
spellingShingle	Ebola HIV MARCH8 class I fusion protein furin glycosylation Microbiology QR1-502 Changqing Yu Sunan Li Xianfeng Zhang Ilyas Khan Iqbal Ahmad Yulong Zhou Shuo Li Jing Shi Yu Wang Yong-Hui Zheng MARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation
description	ABSTRACT Membrane-associated RING-CH-type 8 (MARCH8) strongly blocks human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) incorporation into virions by downregulating its cell surface expression, but the mechanism is still unclear. We now report that MARCH8 also blocks the Ebola virus (EBOV) glycoprotein (GP) incorporation via surface downregulation. To understand how these viral fusion proteins are downregulated, we investigated the effects of MARCH8 on EBOV GP maturation and externalization via the conventional secretion pathway. MARCH8 interacted with EBOV GP and furin when detected by immunoprecipitation and retained the GP/furin complex in the Golgi when their location was tracked by a bimolecular fluorescence complementation (BiFC) assay. MARCH8 did not reduce the GP expression or affect the GP modification by high-mannose N-glycans in the endoplasmic reticulum (ER), but it inhibited the formation of complex N-glycans on the GP in the Golgi. Additionally, the GP O-glycosylation and furin-mediated proteolytic cleavage were also inhibited. Moreover, we identified a novel furin cleavage site on EBOV GP and found that only those fully glycosylated GPs were processed by furin and incorporated into virions. Furthermore, the GP shedding and secretion were all blocked by MARCH8. MARCH8 also blocked the furin-mediated cleavage of HIV-1 Env (gp160) and the highly pathogenic avian influenza virus H5N1 hemagglutinin (HA). We conclude that MARCH8 has a very broad antiviral activity by prohibiting different viral fusion proteins from glycosylation and proteolytic cleavage in the Golgi, which inhibits their transport from the Golgi to the plasma membrane and incorporation into virions. IMPORTANCE Enveloped viruses express three classes of fusion proteins that are required for their entry into host cells via mediating virus and cell membrane fusion. Class I fusion proteins are produced from influenza viruses, retroviruses, Ebola viruses, and coronaviruses. They are first synthesized as a type I transmembrane polypeptide precursor that is subsequently glycosylated and oligomerized. Most of these precursors are cleaved en route to the plasma membrane by a cellular protease furin in the late secretory pathway, generating the trimeric N-terminal receptor-binding and C-terminal fusion subunits. Here, we show that a cellular protein, MARCH8, specifically inhibits the furin-mediated cleavage of EBOV GP, HIV-1 Env, and H5N1 HA. Further analyses uncovered that MARCH8 blocked the EBOV GP glycosylation in the Golgi and inhibited its transport from the Golgi to the plasma membrane. Thus, MARCH8 has a very broad antiviral activity by specifically inactivating different viral fusion proteins.
format	article
author	Changqing Yu Sunan Li Xianfeng Zhang Ilyas Khan Iqbal Ahmad Yulong Zhou Shuo Li Jing Shi Yu Wang Yong-Hui Zheng
author_facet	Changqing Yu Sunan Li Xianfeng Zhang Ilyas Khan Iqbal Ahmad Yulong Zhou Shuo Li Jing Shi Yu Wang Yong-Hui Zheng
author_sort	Changqing Yu
title	MARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation
title_short	MARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation
title_full	MARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation
title_fullStr	MARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation
title_full_unstemmed	MARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation
title_sort	march8 inhibits ebola virus glycoprotein, human immunodeficiency virus type 1 envelope glycoprotein, and avian influenza virus h5n1 hemagglutinin maturation
publisher	American Society for Microbiology
publishDate	2020
url	https://doaj.org/article/2072e260d8684d80bb2cee0ec0199e67
work_keys_str_mv	AT changqingyu march8inhibitsebolavirusglycoproteinhumanimmunodeficiencyvirustype1envelopeglycoproteinandavianinfluenzavirush5n1hemagglutininmaturation AT sunanli march8inhibitsebolavirusglycoproteinhumanimmunodeficiencyvirustype1envelopeglycoproteinandavianinfluenzavirush5n1hemagglutininmaturation AT xianfengzhang march8inhibitsebolavirusglycoproteinhumanimmunodeficiencyvirustype1envelopeglycoproteinandavianinfluenzavirush5n1hemagglutininmaturation AT ilyaskhan march8inhibitsebolavirusglycoproteinhumanimmunodeficiencyvirustype1envelopeglycoproteinandavianinfluenzavirush5n1hemagglutininmaturation AT iqbalahmad march8inhibitsebolavirusglycoproteinhumanimmunodeficiencyvirustype1envelopeglycoproteinandavianinfluenzavirush5n1hemagglutininmaturation AT yulongzhou march8inhibitsebolavirusglycoproteinhumanimmunodeficiencyvirustype1envelopeglycoproteinandavianinfluenzavirush5n1hemagglutininmaturation AT shuoli march8inhibitsebolavirusglycoproteinhumanimmunodeficiencyvirustype1envelopeglycoproteinandavianinfluenzavirush5n1hemagglutininmaturation AT jingshi march8inhibitsebolavirusglycoproteinhumanimmunodeficiencyvirustype1envelopeglycoproteinandavianinfluenzavirush5n1hemagglutininmaturation AT yuwang march8inhibitsebolavirusglycoproteinhumanimmunodeficiencyvirustype1envelopeglycoproteinandavianinfluenzavirush5n1hemagglutininmaturation AT yonghuizheng march8inhibitsebolavirusglycoproteinhumanimmunodeficiencyvirustype1envelopeglycoproteinandavianinfluenzavirush5n1hemagglutininmaturation
_version_	1718426891880235008

MARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation

Ejemplares similares